Form 8-K - Current report:
SEC Accession No. 0001104659-25-009368
Filing Date
2025-02-05
Accepted
2025-02-05 07:17:09
Documents
15
Period of Report
2025-02-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255498d1_8k.htm   iXBRL 8-K 33043
2 EXHIBIT 99.1 tm255498d1_ex99-1.htm EX-99.1 42127
3 GRAPHIC tm255498d1_ex99-1img001.jpg GRAPHIC 3167
  Complete submission text file 0001104659-25-009368.txt   267673

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA zbio-20250205.xsd EX-101.SCH 3015
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE zbio-20250205_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zbio-20250205_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm255498d1_8k_htm.xml XML 3794
Mailing Address 852 WINTER STREET, SUITE 250 WALTHAM MA 02451
Business Address 852 WINTER STREET, SUITE 250 WALTHAM MA 02451 857-271-2954
Zenas BioPharma, Inc. (Filer) CIK: 0001953926 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42270 | Film No.: 25590887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)